Excess Mortality Among HIV-Infected Patients Diagnosed With Substance Use Dependence or Abuse Receiving Care in a Fully Integrated Medical Care Program

Alcoholism: Clinical and Experimental Research

Volumn 35, Issue 2, 2011, Pages 203-210

  DeLorenze, Gerald N ^a   Weisner, Constance ^a,b   Tsai, Ai Lin ^a   Satre, Derek D ^a,b   Quesenberry Jr, Charles P ^a  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV; Mortality; Substance Dependence and Abuse

Indexed keywords

ILLICIT DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALCOHOLISM; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG DEPENDENCE; FEMALE; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL SERVICE; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; SUBSTANCE ABUSE;

EID: 78851469182     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2010.01335.x     Document Type: Article

References (30)

1. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL (2006) Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis 42:716-721.
2. Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II - the design and analysis of cohort studies. IARC Sci Publ 82:1-406.
3. Conigliaro J, Madenwald T, Bryant K, Braithwaite S, Gordon A, Fultz SL, Maisto S, Samet J, Kraemer K, Cook R, Day N, Roach D, Richey S, Justice A (2004) The Veterans Aging Cohort Study: observational studies of alcohol use, abuse, and outcomes among human immunodeficiency virus-infected veterans. Alcohol Clin Exp Res 28:313-321.
4. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP (1998) Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280:1497-1503.
5. Estrada AL (2005) Health disparities among African-American and Hispanic drug injectors - HIV, AIDS, hepatitis B virus and hepatitis C virus: a review. AIDS 19(Suppl 3):S47-S52.
6. Fonseca MG, Lucena Fde F, Sousa A, Bastos FI (2007) AIDS mortality, "race or color, "and social inequality in a context of universal access to highly active antiretroviral therapy (HAART) in Brazil, 1999-2004. Cad Saude Publica 23(Suppl 3):S445-S455.
7. French AL, Gawel SH, Hershow R, Benning L, Hessol NA, Levine AM, Anastos K, Augenbraun M, Cohen MH (2009) Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 51:399-406.
8. Garcia de la Hera M, Ferreros I, del Amo J, Garcia de Olalla P, Perez Hoyos S, Muga R, del Romero J, Guerrero R, Hernandez-Aguado I (2004) Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J Epidemiol Community Health 58:944-950.
9. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA (2001) Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS 15:1295-1302.
10. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS (1999) Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 160:659-665.
11. Kohli R, Lo Y, Howard AA, Buono D, Floris-Moore M, Klein RS, Schoenbaum EE (2005) Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 41:864-872.
12. Krieger N (1992) Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 82:703-710.
13. Lucas GM, Gebo KA, Chaisson RE, Moore RD (2002) Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 16:767-774.
14. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD (2006) Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 163:412-420.
15. Lum PJ, Tulsky JP (2006) The medical management of opioid dependence in HIV primary care settings. Curr HIV/AIDS Rep 3:195-204.
16. Mertens JR, Weisner C, Ray GT, Fireman B, Walsh K (2005) Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions, and costs. Alcohol Clin Exp Res 29:989-998.
17. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren J (2004) Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 18:2333-2337.
18. Muga R, Langohr K, Tor J, Sanvisens A, Serra I, Rey-Joly C, Munoz A (2007) Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Clin Infect Dis 45:370-376.
19. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ (2001) Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135:17-26.
20. Nash D, Katyal M, Shah S (2005) Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993-2001. J Urban Health 82:584-600.
21. Pezzotti P, Galai N, Vlahov D, Rezza G, Lyles CM, Astemborski J (1999) Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol 20:275-282.
22. Poundstone KE, Chaisson RE, Moore RD (2001) Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 15:1115-1123.
23. Ray GT, Mertens JR, Weisner C (2007) The excess medical cost and health problems of family members of persons diagnosed with alcohol or drug problems. Med Care 45:116-122.
24. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV (2006) Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 145:397-406.
25. Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA (2006) A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 43(Suppl 4):S184-S190.
26. Thorpe LE, Frederick M, Pitt J, Cheng I, Watts DH, Buschur S, Green K, Zorrilla C, Landesman SH, Hershow RC (2004) Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndr 37:1423-1430.
27. Walley AY, Cheng DM, Libman H, Nunes D, Horsburgh CR Jr, Saitz R, Samet JH (2008) Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS 22:415-420.
28. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y (2001) Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA 286:1715-1723.
29. Woldemichael G, Christiansen D, Thomas S, Benbow N (2009) Demographic characteristics and survival with AIDS: health disparities in Chicago, 1993-2001. Am J Public Health 99(Suppl 1):S118-S123.
30. Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, Montaner JS (2008) Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 300:550-554.